Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest announcement is out from Dynavax ( (DVAX) ).
On February 3, 2025, Justin Burgess announced his resignation from Dynavax Technologies Corporation, where he served as the principal accounting officer, effective on or around March 3, 2025. The company plans to appoint Kelly MacDonald, the current Chief Financial Officer, as the new principal accounting officer without changing her compensation, indicating a seamless transition in leadership roles within the company.
More about Dynavax
Dynavax Technologies Corporation operates in the biotechnology industry, focusing on developing and commercializing novel immunotherapies and vaccines.
YTD Price Performance: 1.63%
Average Trading Volume: 1,944,210
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: $1.72B
For a thorough assessment of DVAX stock, go to TipRanks’ Stock Analysis page.
